Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/127114
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors
Author: Tadesse, S.
Zhu, G.
Mekonnen, L.
Lenjisa, J.
Yu, M.
Brown, M.
Wang, S.
Citation: Future Medicinal Chemistry, 2017; 9(13):1495-1506
Publisher: Future Science
Issue Date: 2017
ISSN: 1756-8919
1756-8927
Statement of
Responsibility: 
Solomon Tadesse, Ge Zhu, Laychiluh B Mekonnen, Jimma L Lenjisa, Mingfeng Yu, Michael P Brown, Shudong Wang
Abstract: Inhibitors of CDK4/6 have emerged as a powerful class of therapeutics for treatment of several malignancies. We herein describe the identification of a new series of molecules that demonstrated excellent selectivity for CDK4/6 over CDKs1, 7 and 9.Medicinal chemistry optimization led to the discovery of 58 and 69 that inhibited CDK4 and CDK4/6, respectively, with high potency and selectivity, and 58 and 69 exhibited potent antiproliferative activities in a panel of human cancer cell lines including leukemia, and cancers of the breast, colon, ovary, pancreas and prostate.Compounds 58 and 69 caused remarkable growth inhibition of melanoma cells, particularly the cells harboring multiple BRAF and NRAS mutations, via a CDK4/6-targeted mechanism of action. [Formula: see text].
Keywords: Cell Line, Tumor
Humans
Amines
Pyridines
Pyrimidines
Thiazoles
GTP Phosphohydrolases
Proto-Oncogene Proteins B-raf
Retinoblastoma Protein
Membrane Proteins
Protein Kinase Inhibitors
Cell Proliferation
Binding Sites
Protein Structure, Tertiary
Protein Binding
Structure-Activity Relationship
Phosphorylation
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
G1 Phase Cell Cycle Checkpoints
Rights: © 2017 Future Science Ltd.
DOI: 10.4155/fmc-2017-0076
Appears in Collections:Aurora harvest 4
Biochemistry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.